Evidence map›Paper›PMID 40421127›Full record

ArticleJAC-antimicrobial resistance2025

Detection of rare β-lactamase

Luciano A Palomino-Kobayashi, Rocío Egoávil-Espejo, Gina Salvador-Luján, Pamela Yáñez, Ronnie G Gavilán, Maria J Pons, Joaquim Ruiz

Abstract read
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Circulation of ESBL-producingFrontiers in public health · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luciano A Palomino-KobayashiPrograma de Doctorado en Ciencias de la Salud, Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Perú.ORCID https://orcid.org/0000-0003-4832-9369
Rocío Egoávil-EspejoGrupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos-'One Health', Universidad Científica del Sur, Lima, Perú.
Gina Salvador-LujánLaboratorio de Microbiología, Hospital Militar Central, Lima, Perú.ORCID https://orcid.org/0000-0001-6617-6402
Pamela YáñezInstituto Nacional de Salud, Lima, Perú.
Ronnie G GavilánInstituto Nacional de Salud, Lima, Perú.ORCID https://orcid.org/0000-0003-1437-5607
Maria J PonsGrupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos-'One Health', Universidad Científica del Sur, Lima, Perú.
Joaquim RuizGrupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos-'One Health', Universidad Científica del Sur, Lima, Perú.ORCID https://orcid.org/0000-0002-4431-2036

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Objectives: To characterize a Methods: Susceptibility to amoxicillin/clavulanic acid, amoxicillin/sulbactam, piperacillin/tazobactam, aztreonam, ceftriaxone, cefotaxime, ceftazidime, ceftazidime/avibactam, cefepime, imipenem, meropenem, ciprofloxacin, trimethoprim/sulfamethoxazole, gentamicin, amikacin and tigecycline was determined using the Kirby-Bauer disc diffusion method. Detection of Results: The isolate showed resistance to all the tested antibiotics except for ceftazidime/avibactam, carbapenems and tigecycline. Illumina WGS showed the presence of Conclusions: This study highlights the importance of genomic surveillance of uncommon antimicrobial resistance genes such as

Identifiers

PMID40421127
PMCPMC12103947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.